Cancer Research  AM No Date
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kostourou, V.
Right arrow Articles by Griffiths, J. R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kostourou, V.
Right arrow Articles by Griffiths, J. R.
[Cancer Research 63, 4960-4966, August 15, 2003]
© 2003 American Association for Cancer Research


Regular Articles

Effects of Overexpression of Dimethylarginine Dimethylaminohydrolase on Tumor Angiogenesis Assessed by Susceptibility Magnetic Resonance Imaging1

Vassiliki Kostourou2, Simon P. Robinson3, Guy St. J. Whitley and John R. Griffiths

Department of Basic Medical Sciences, St. George’s Hospital Medical School, London SW17 ORE, United Kingdom

Intracellular factors that regulate nitric oxide (NO) synthesis represent important targets in tumor progression. Overexpression of dimethylarginine dimethylaminohydrolase (DDAH), which metabolizes the endogenous inhibitors of NO synthesis asymmetric dimethylarginine and N-monomethyl-L-arginine, results in C6 gliomas with enhanced growth rate compared with wild type. To investigate the effects of DDAH on tumor vascular morphogenesis in vivo, we have measured the transverse relaxation rates R2* and R2 in clone D27 gliomas overexpressing DDAH and C6 wild-type gliomas using intrinsic susceptibility magnetic resonance imaging (MRI), sensitive to changes in endogenous [deoxyhemoglobin], and susceptibility contrast-enhanced MRI using the intravascular blood pool contrast agent NC100150, and we compared the results with fluorescence microscopy of the tumor uptake of the perfusion marker Hoechst 33342. The baseline R2* was significantly faster in the D27 tumors, consistent with a greater vascular development (P < 0.02, ANOVA). There was no significant difference between the response of the two tumor types to hypercapnia (5% CO2/95% air), used as a probe for vascular maturation, or hyperoxia (5% CO2/95% O2), used as a probe for vascular function. NC100150 increased the R2* and R2 rates of both tumor types and demonstrated a significantly larger blood volume in the D27 tumors (P < 0.02, ANOVA). This correlated with a significantly greater uptake of Hoechst 33342 in the D27 tumors compared with C6 wild-type tumors (P < 0.02, ANOVA). Despite the increased tumor blood volume, the {Delta}R2*/{Delta}R2 ratio, an index of microvessel size, showed that the capillaries in the two tumor types were of a similar caliber. The data highlight the potential of susceptibility MRI-derived quantitative end points to noninvasively assess tumor angiogenesis, and in this regard, the use of intravascular blood pool contrast agents such as NC100150 appears very promising. Overexpression of DDAH results in increased neovascularization of C6 gliomas in vivo. The lack of significant difference in hypercapnic/hyperoxic response between the C6 and D27 tumors and the similar vessel caliber are also consistent with a role for DDAH in the initial stages of vasculogenesis.




This article has been cited by other articles:


Home page
JPEN J Parenter Enteral NutrHome page
M. C. Richir, R. H. Bouwman, T. Teerlink, M. P.C. Siroen, T. P.G.M. de Vries, and P. A.M. van Leeuwen
The Prominent Role of the Liver in the Elimination of Asymmetric Dimethylarginine (ADMA) and the Consequences of Impaired Hepatic Function
JPEN J Parenter Enteral Nutr, November 1, 2008; 32(6): 613 - 621.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
S. J. Nicholls, Z. Wang, R. Koeth, B. Levison, B. DelFraino, V. Dzavik, O. W. Griffith, D. Hathaway, J. A. Panza, S. E. Nissen, et al.
Metabolic Profiling of Arginine and Nitric Oxide Pathways Predicts Hemodynamic Abnormalities and Mortality in Patients With Cardiogenic Shock After Acute Myocardial Infarction
Circulation, November 13, 2007; 116(20): 2315 - 2324.
[Abstract] [Full Text] [PDF]


Home page
Clin. Chem.Home page
R. Maas, F. Schulze, J. Baumert, H. Lowel, K. Hamraz, E. Schwedhelm, W. Koenig, and R. H. Boger
Asymmetric Dimethylarginine, Smoking, and Risk of Coronary Heart Disease in Apparently Healthy Men: Prospective Analysis from the Population-Based Monitoring of Trends and Determinants in Cardiovascular Disease/Kooperative Gesundheitsforschung in der Region Augsburg Study and Experimental Data
Clin. Chem., April 1, 2007; 53(4): 693 - 701.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
J. Zhang, B. Peng, and X. Chen
Expressions of Nuclear Factor {kappa}B, Inducible Nitric Oxide Synthase, and Vascular Endothelial Growth Factor in Adenoid Cystic Carcinoma of Salivary Glands: Correlations with the Angiogenesis and Clinical Outcome
Clin. Cancer Res., October 15, 2005; 11(20): 7334 - 7343.
[Abstract] [Full Text] [PDF]


Home page
Vasc MedHome page
R. Maas
Pharmacotherapies and their influence on asymmetric dimethylargine (ADMA)
Vascular Medicine, July 1, 2005; 10(1_suppl): S49 - S57.
[Abstract] [PDF]


Home page
Vasc MedHome page
T. Teerlink
ADMA metabolism and clearance
Vascular Medicine, July 1, 2005; 10(1_suppl): S73 - S81.
[Abstract] [PDF]


Home page
Vasc MedHome page
R. Maas
Pharmacotherapies and their influence on asymmetric dimethylargine (ADMA)
Vascular Medicine, May 1, 2005; 10(2_suppl): S49 - S57.
[Abstract] [PDF]


Home page
Vasc MedHome page
T. Teerlink
ADMA metabolism and clearance
Vascular Medicine, May 1, 2005; 10(2_suppl): S73 - S81.
[Abstract] [PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
P. Vallance and J. Leiper
Cardiovascular Biology of the Asymmetric Dimethylarginine:Dimethylarginine Dimethylaminohydrolase Pathway
Arterioscler. Thromb. Vasc. Biol., June 1, 2004; 24(6): 1023 - 1030.
[Abstract] [Full Text] [PDF]


Home page
J. Am. Soc. Nephrol.Home page
K. Manotham, T. Tanaka, M. Matsumoto, T. Ohse, T. Miyata, R. Inagi, K. Kurokawa, T. Fujita, and M. Nangaku
Evidence of Tubular Hypoxia in the Early Phase in the Remnant Kidney Model
J. Am. Soc. Nephrol., May 1, 2004; 15(5): 1277 - 1288.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2003 by the American Association for Cancer Research.